WO2016062282A1 - 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用以保护胰脏及防止血糖升高的用途 - Google Patents
巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用以保护胰脏及防止血糖升高的用途 Download PDFInfo
- Publication number
- WO2016062282A1 WO2016062282A1 PCT/CN2015/092770 CN2015092770W WO2016062282A1 WO 2016062282 A1 WO2016062282 A1 WO 2016062282A1 CN 2015092770 W CN2015092770 W CN 2015092770W WO 2016062282 A1 WO2016062282 A1 WO 2016062282A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mip
- macrophage inflammatory
- protein
- inflammatory protein
- inhibitor
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the present invention relates to the use of macrophage inflammatory protein-1 ⁇ (MIP-1 ⁇ ) inhibitors to protect the pancreas. More particularly, the present invention relates to the use of MIP-1 ⁇ inhibitors for maintaining insulin secretion in diabetic patients and preventing elevated blood glucose levels.
- MIP-1 ⁇ macrophage inflammatory protein-1 ⁇
- the number of patients with clinical diabetes has continued to increase year by year in the world or in Asian countries, especially in mainland China, Taiwan, Japan, and India.
- the number of type 2 diabetes in China is now close to 10% of the total population and is still increasing. Therefore, there is an urgent need for drug development in diabetes.
- the blood glucose elevation of diabetes is mainly caused by an increase in insulin resistance (type 2 diabetes) and impaired inflammation of the pancreatic pancreatic islet cells (type 1 and type 2 diabetes), so that the pancreas secretes insulin insufficiently. Reduce the intake of foreign substances and the sugar produced in the body.
- the blood sugar control of clinical diabetes is mainly to stimulate the pancreas to secrete insulin (to treat type 2 diabetes), to reduce the peripheral tissue insulin resistance (to treat type 2 diabetes), and to reduce intestinal glucose uptake and absorption (treatment of type 1 and type 2). Diabetes), or increase the urine sugar exclusion (treatment of type 1 and type 2 diabetes).
- the pancreatic pancreatic islet cells eventually become inflammatory and destructive, resulting in a severely insufficient insulin secretion, which must be supplemented by injection or inhalation of insulin.
- the drugs that are currently in existence or in development do not directly protect the pancreas (pancreatic islet cells), reduce or restore their damage, and thereby maintain insulin secretion. Therefore, the present invention has attempted to develop a drug which can prevent an increase in blood sugar of a diabetic person by a therapeutic route for protecting pancreatic islets inflammation and destruction by protecting the pancreas of a diabetic person.
- Macrophage inflammatory protein-1 ⁇ is a member of the CC cytokine family, which is the first to isolate free lipopolysaccharide-activated macrophage cultures (Lodi PJ et al., Science 263: 1762-1767). , 1994), with a molecular weight of 7.8 kilodaltons, and its protein structure consists of 92 amino acid precursors.
- MIP-1 ⁇ has been observed to be up-regulated in patients with DM and cardiovascular disease (Tatara, Y. et al., JMol Cell Cardiol 47: 104-111, 2009; Mirabelli-Badenier, M. et al., Thromb Haemost 105 :409-420, 2011).
- MIP-1 ⁇ further performs its biochemical function by binding to the CC cytokine receptor (CCR, which belongs to the G-protein-and-type receptor superfamily) on the cell surface.
- CCR CC cytokine receptor
- the macrophage inflammatory protein-1 ⁇ monoclonal antibody we use can antagonize the regulation of CCR5.
- the presence of CCR5 in the pancreas may be associated with the development of isletitis and spontaneous type 1 diabetes (Cameron MJ et al, J Immunol 165: 1102-1110, 2000).
- macrophage inflammatory protein-1 ⁇ in blood is positively correlated with diabetes and cardiovascular disease. Therefore, we have developed a new therapeutic strategy for the prevention and treatment of inflammation of the pancreatic islets of diabetic patients by using macrophage inflammatory protein (MIP)-1 to protect the pancreas from inflammation, thereby maintaining its insulin secretion and controlling blood sugar.
- MIP macrophage inflammatory protein
- the present invention finds that in the first and second types of diabetic animal models, direct inhibition of macrophage inflammatory protein-1 ⁇ (for example, by single antibody) can protect the pancreas and maintain its The effect of insulin secretion and the blood sugar level will not continue to rise.
- one aspect of the present invention relates to the use of a macrophage inflammatory protein-1 ⁇ inhibitor for the preparation of a pharmaceutical composition for protecting pancreatic function in a diabetic patient, wherein said protecting a pancreatic function of a diabetic patient comprises preventing a diabetic patient Pancreatic islet cells are damaged.
- the pharmaceutical composition is for maintaining insulin secretion in a diabetic patient.
- the pharmaceutical composition is for preventing an increase in blood glucose in a diabetic patient.
- the macrophage inflammatory protein-1 ⁇ inhibitor is a compound capable of reducing or inhibiting the biological activity of macrophage inflammatory protein-1 ⁇ .
- the macrophage inflammatory protein-1 ⁇ inhibitor is a ligand compound having binding specificity for macrophage inflammatory protein-1 ⁇ , such as an anti-macrophage inflammatory protein- 1 ⁇ antibody or antagonist.
- the anti-macrophage inflammatory protein-1 ⁇ antibody is a monoclonal antibody or a plurality of antibodies.
- the anti-macrophage inflammatory protein-1 ⁇ antibody is a monoclonal antibody, or an antibody fragment thereof that binds to at least a peptide fragment of macrophage inflammatory protein-1 ⁇ .
- the peptide fragment of macrophage inflammatory protein-1 ⁇ comprises the amino acid sequence 46SFMDDYYET54 (SEQ ID NO: 1), or 62AVVFLTKRGRQIC74 (SEQ ID NO: 2).
- Figure 1 is a graph showing the protective effect of MIP-1 ⁇ -inhibitor on the pancreas of type 1 diabetic mice, and inhibiting the activity of macrophage inflammatory protein (MIP)-1 ⁇ in vivo by monoclonal antibody (mAb), which can effectively enhance blood. The amount of insulin.
- MIP macrophage inflammatory protein
- Fig. 2 is a graph showing the results of observation of a streptozotocin (STZ)-induced inflammatory state in pancreatic tissue of a first-type diabetic animal model by section staining.
- the red fluorescence is pancreatic islet cells.
- FIG. 3 is a graph showing the content of macrophage inflammatory protein (MIP)-1 ⁇ protein in blood of normal mice (non-DM control group) and type 2 diabetic mice.
- MIP macrophage inflammatory protein
- Fig. 4 is a graph showing the results of observation of a streptozotocin (STZ)-induced inflammatory state in pancreatic tissue of a first-type diabetic animal model by section staining.
- the red fluorescence is pancreatic islet cells.
- Figure 5 shows the Western blot and statistical analysis.
- the content of IL6 and IL8 in the mouse pancreas (n 3).
- #P ⁇ 0.05, ##P ⁇ 0.01 is compared to the normal control group of mice.
- *P ⁇ 0.05, **P ⁇ 0.01 is compared to DM mice that have not been treated with antibodies.
- Figure 6A shows the increase in macrophage inflammatory protein (MIP)-1 ⁇ concentration in culture medium with different doses of STZ(or) treatment with pancreatic islet cell (NIT-1) NIT-1 cell proliferation.
- MIP macrophage inflammatory protein
- MIP-1 ⁇ -inhibitor means at least one which reduces the MIP-1 ⁇ protein content and/or decreases the MIP-1 ⁇ protein.
- An active compound An active compound.
- the MIP-1 ⁇ -inhibitor compound reduces at least one biological activity of the MIP-1 ⁇ protein by at least about 10%, 25%, 50%, 75% or more.
- the MIP-1 ⁇ -inhibitor compound protects the pancreas and prevents elevated blood glucose by reducing the amount of MIP-1 ⁇ protein expression.
- MIP-1 ⁇ protein expression For example, siRNA, antisense nucleic acid or ribozyme targeting MIP-1 ⁇ can be used to inhibit intracellular MIP-1 ⁇ gene expression.
- the amount of MIP-1 ⁇ protein expression can also be reduced by modulating the transcription of a gene encoding a MIP-1 ⁇ protein or by restoring the corresponding mRNA.
- the MIP-1 ⁇ -inhibitor compound protects the pancreas and prevents or inhibits the biological activity of the MIP-1 ⁇ protein by binding to the MIP-1 ⁇ protein. Blood sugar rises.
- an antibody against MIP-1 ⁇ can be used to compete with a MIP-1 ⁇ protein for binding to a receptor on the cell surface while inhibiting the biological activity of the MIP-1 ⁇ protein in vivo.
- the antibodies may include full-length monoclonal antibodies, polyclonal antibodies, multispecific antibodies (eg, bispecific antibodies). And antibody fragments.
- antibody means an immunoglobulin molecule or a fragment thereof that has the ability to specifically bind to a particular antigen.
- An “antibody fragment” comprises a portion of a full length antibody, preferably an antigen-binding region or variable region of an antibody.
- antibody fragments include Fab, Fab', F(ab)2, F(ab')2, F(ab)3, Fv (representatively one of the one-armed VL and VH domains of the antibody), single-stranded Fv (scFv), dsFv, Fd fragments (representatively VH and CH1 domains) and dAb fragments (representatively VH domain); VH, VL and VhH domains; minibodies, dimers ( Diabodies), triabodies, tetrabodies, and kappa antibodies (see, Ill et al., Protein Eng 10:949-57, 1997); camel IgG; and one or more isolated CDRs from antibody fragments Or a multi-specific antibody fragment formed by a functional paratope in which the isolated or antigen-binding residues or polypeptides can bind or bind to each other to form a functional antibody fragment.
- the MIP-1 ⁇ -inhibitor is a monoclonal antibody that specifically binds to a MIP-1 ⁇ protein.
- the anti-MIP-1 ⁇ monoclonal antibody system binds to a major functional site of the MIP-1 ⁇ protein structure.
- the MIP-1 ⁇ -inhibitor eg, an anti-MIP-1 ⁇ monoclonal antibody
- the MIP-1 ⁇ -inhibitor can be linked to an amino acid sequence comprising a MIP-1 ⁇ protein at positions 46-54: SSFMDYYET ( SEQ ID NO: 1), or the amino acid sequence of positions M62-74 of the MIP-1 ⁇ protein: epitope binding of AVVFLTKRGRQIC (SEQ ID NO: 2).
- the antibody may be a humanized or fully humanized monoclonal antibody.
- the pharmaceutical composition according to the invention may comprise at least one MIP-1 ⁇ -inhibitor and one or more physiologically acceptable carriers, diluents or excipients.
- Appropriate pharmaceutical composition forms may be formulated according to the selected route of administration, including (but not limited to) oral preparations such as tablets, capsules, powders, etc., parenteral preparations such as subcutaneous, intramuscular or intraperitoneal injections. And a lyophilized powder combined with a physiological buffer solution before administration.
- Example 1 MIP-1 ⁇ -inhibitor protects the pancreas of a type 1 diabetic animal (streptomycin (STZ)-induced diabetic mouse model) and prevents elevation of blood sugar
- the serum insulin test results of Fig. 1 showed that the serum insulin concentration of the type 1 diabetic mice induced by streptozotocin (STZ)- was significantly lower than that of the normal control mice.
- STZ streptozotocin
- MIP anti-macrophage inflammatory protein
- mAb monoclonal antibody
- pancreatic Insular cells injected with monoclonal antibodies (mAb) against diabetic macrophage inflammatory protein (MIP)-1 ⁇ in diabetic animals (DM+mAb group), can prevent pancreatic islet cells from being damaged by inflammation, and partially maintain pancreatic islets
- mAb monoclonal antibodies
- MIP macrophage inflammatory protein
- Example 2 MIP-1 ⁇ -inhibitor protects the pancreas of type 2 diabetic animals (Leprdb/db mouse model) and prevents blood sugar elevation
- the amount of macrophage inflammatory protein (MIP)-1 ⁇ in the blood of type 2 diabetic animals was significantly higher than that of normal animals.
- injection of monoclonal antibody (mAb) against macrophage inflammatory protein (MIP)-1 ⁇ in vivo can effectively control blood glucose levels, so that they do not continue Raised (Table 2).
- pancreatic islet cells of diabetic mice were severely damaged (red fluorescence was pancreatic islet cells); whereas in type 2 diabetic mice with high blood glucose levels,
- mAb monoclonal antibody
- MIP macrophage inflammatory protein
- pancreas prevents the pancreatic islet cells from being destroyed, while the vitamins continue to secrete insulin to regulate the normal function of blood sugar (Fig. 4).
- Example 3 Protection of MIP-1 ⁇ -inhibitors against pancreatic islet cell damage (streptomycin (STZ)-induced pancreatic cell injury model)
- FIG. 5 show that in a diabetic animal with a high blood sugar level, injection of a monoclonal antibody (mAb) against the macrophage inflammatory protein (MIP)-1 ⁇ in vivo can effectively inhibit the inflammatory substances of the pancreas (pancreatic islet), such as The performance of interleukin-6 (IL-6) and interleukin-8 (IL-8). Therefore, inhibition of macrophage inflammatory protein (MIP)-1 ⁇ protects pancreatic islet cells and reduces the inflammatory response caused by streptozotocin.
- mAb monoclonal antibody
- IL-6 interleukin-6
- IL-8 interleukin-8
- NIT-1 cells a pancreatic ⁇ -cell strain established from transgenic nod/lt mice
- STZ 0.75, 1.5, 3, 6 mM
- NIT-1 cells were treated with STZ for 24 hours, and then treated with no, low dose (0.3 ⁇ g/ml) or high dose (30 ⁇ g/ml) of MIP-1 ⁇ antibody (R&D system) for 4 hours.
- the proliferation of NIT-1 cells was assessed by MTT assay. The results are shown in Figure 6.
- the toxicity of streptozotocin (STZ 1.5, STZ 3) to pancreatic islet cells (NIT-1) increased with the dose of streptozotocin.
- the monoclonal antibody (mAb) against the cell-produced macrophage inflammatory protein (MIP)-1 ⁇ can directly improve the inhibition of the number of pancreatic islet cells (NIT-1) by streptozotocin (STZ 1.5, STZ3). Destructive effect. Therefore, inhibition of macrophage inflammatory protein (MIP)-1 ⁇ can directly protect pancreatic islet cells, Low-chain zoloumycin damage to pancreatic islet cells.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
- 一种巨噬细胞发炎蛋白-1β抑制剂用于制备保护糖尿病患者胰脏功能的医药组成物的用途,其中该保护糖尿病患者胰脏功能是包含防止糖尿病患者胰小岛细胞受损。
- 如权利要求1所述的用途,其中该医药组成物是用于维持糖尿病患者的胰岛素分泌。
- 如权利要求2所述的用途,其中该医药组成物是用于防止糖尿病患者血糖升高。
- 如权利要求1所述的用途,其中该巨噬细胞发炎蛋白-1β抑制剂为能够减低或抑制巨噬细胞发炎蛋白-1β的生物活性的化合物。
- 如权利要求1或4所述的用途,其中该巨噬细胞发炎蛋白-1β抑制剂为对于巨噬细胞发炎蛋白-1β具有结合特异性的配体化合物。
- 如权利要求5所述的用途,其中该巨噬细胞发炎蛋白-1β抑制剂为抗-巨噬细胞发炎蛋白-1β抗体。
- 如权利要求6所述的用途,其中该MIP-1β-抑制剂为与MIP-1β蛋白或其片段特异性结合的抗-MIP-1β单株抗体。
- 如权利要求7所述的用途,其中该抗-MIP-1β单株抗体是与MIP-1β蛋白结构上的主要功能作用部位结合。
- 如权利要求7或8所述的用途,其中该抗-MIP-1β单株抗体是与一包含MIP-1β蛋白的胺基酸序列位置46~54:SFVMDYYET(SEQ ID NO:1)的肽类片段结合。
- 如权利要求7或8所述的用途,其中该抗-MIP-1β单株抗体是与一包含MIP-1β蛋白的胺基酸序列位置62~74:AVVFLTKRGRQIC (SEQ ID NO:2)的肽类片段结合。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/521,116 US20180134782A1 (en) | 2014-10-24 | 2015-10-23 | Use of Macrophage inflammatory protein-1Beta (MIP-1Beta) inhibitor to protect pancreas and prevent blood sugar from rising |
JP2017522350A JP6860480B2 (ja) | 2014-10-24 | 2015-10-23 | マクロファージ炎症性タンパク質−1β抑制剤の使用方法 |
EP15851823.3A EP3210616A4 (en) | 2014-10-24 | 2015-10-23 | Use of macrophage inflammatory protein-1 (mip-1 ) inhibitor to protect pancreas and prevent blood sugar from rising |
CN201580057808.6A CN107206051A (zh) | 2014-10-24 | 2015-10-23 | 巨噬细胞发炎蛋白‑1β(MIP‑1β)抑制剂用以保护胰脏及防止血糖升高的用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462068475P | 2014-10-24 | 2014-10-24 | |
US62/068,475 | 2014-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016062282A1 true WO2016062282A1 (zh) | 2016-04-28 |
Family
ID=55760316
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/092770 WO2016062282A1 (zh) | 2014-10-24 | 2015-10-23 | 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用以保护胰脏及防止血糖升高的用途 |
PCT/CN2015/092766 WO2016062280A1 (zh) | 2014-10-24 | 2015-10-23 | 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用于促进血管新生以改善组织缺血及糖尿病血管病变的用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/092766 WO2016062280A1 (zh) | 2014-10-24 | 2015-10-23 | 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用于促进血管新生以改善组织缺血及糖尿病血管病变的用途 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20180134782A1 (zh) |
EP (2) | EP3210616A4 (zh) |
JP (3) | JP2018502055A (zh) |
CN (2) | CN107206051A (zh) |
TW (2) | TWI566780B (zh) |
WO (2) | WO2016062282A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019037067A1 (zh) * | 2017-08-25 | 2019-02-28 | 法玛科技顾问股份有限公司 | 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用以治疗及控管动脉粥状硬化的用途 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200172609A1 (en) * | 2017-08-10 | 2020-06-04 | National Yang-Ming University | Method for preventing or treating atherosclerosis |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130058970A1 (en) * | 2011-09-06 | 2013-03-07 | Selecta Biosciences, Inc. | Induced tolerogenic dendritic cells to reduce systemic inflammatory cytokines |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003294290A1 (en) * | 2002-11-15 | 2004-06-15 | Morehouse School Of Medicine | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation. |
CN1589904A (zh) * | 2003-09-01 | 2005-03-09 | 北京大学 | 造血干细胞动员剂制备治疗糖尿病药物的用途 |
US8003111B2 (en) * | 2005-04-06 | 2011-08-23 | Ibc Pharmaceuticals, Inc. | Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo |
CN101573377A (zh) * | 2006-02-17 | 2009-11-04 | 拉帕波特家族医学科学研究所 | 治疗ccr5/ccr5配体相关疾病的分子和用这种分子治疗该疾病的方法 |
CA2639115A1 (en) * | 2006-02-17 | 2007-08-23 | Rappaport Family Institute For Research In The Medical Sciences | Molecules and methods of using same for treating ccr5/ccr5 ligands associated diseases |
WO2008145142A1 (en) * | 2007-05-31 | 2008-12-04 | Genmab A/S | Stable igg4 antibodies |
WO2009015472A1 (en) * | 2007-07-30 | 2009-02-05 | London Health Sciences Centre Research Inc. | Methods to diagnose type 1 diabetes by measuring cytokine and/or chemokine expression profiles. |
ES2617029T3 (es) * | 2009-08-03 | 2017-06-15 | Global Eagle Entertainment Inc | Sistema y método para habilitar una antena de comunicaciones de apertura ultrapequeña usando replicación espectral y combinación coherente de frecuencia y fase |
US20120225301A1 (en) * | 2009-08-28 | 2012-09-06 | Hunt Bryan V | Optical device with antistatic coating |
US8313747B2 (en) * | 2009-08-28 | 2012-11-20 | Vlst Corporation | Antikine antibodies that bind to multiple CC chemokines |
CN103813788A (zh) * | 2011-05-03 | 2014-05-21 | 罗切斯特大学 | 治疗前列腺癌的方法 |
-
2015
- 2015-10-20 TW TW104134410A patent/TWI566780B/zh active
- 2015-10-20 TW TW104134416A patent/TWI576112B/zh active
- 2015-10-23 US US15/521,116 patent/US20180134782A1/en not_active Abandoned
- 2015-10-23 EP EP15851823.3A patent/EP3210616A4/en not_active Withdrawn
- 2015-10-23 JP JP2017522552A patent/JP2018502055A/ja active Pending
- 2015-10-23 US US15/521,153 patent/US20180044413A1/en not_active Abandoned
- 2015-10-23 CN CN201580057808.6A patent/CN107206051A/zh active Pending
- 2015-10-23 WO PCT/CN2015/092770 patent/WO2016062282A1/zh active Application Filing
- 2015-10-23 EP EP15852326.6A patent/EP3211004B1/en active Active
- 2015-10-23 WO PCT/CN2015/092766 patent/WO2016062280A1/zh active Application Filing
- 2015-10-23 CN CN201580057781.0A patent/CN107108719A/zh active Pending
- 2015-10-23 JP JP2017522350A patent/JP6860480B2/ja active Active
-
2019
- 2019-08-22 JP JP2019152034A patent/JP2019196409A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130058970A1 (en) * | 2011-09-06 | 2013-03-07 | Selecta Biosciences, Inc. | Induced tolerogenic dendritic cells to reduce systemic inflammatory cytokines |
Non-Patent Citations (2)
Title |
---|
LI, GUILIN; ET AL.: "Role of chemokine (c-c motif) ligand 5 and its receptor CCR5 in diabetic complication", CHINESE PHARMACOLOGICAL BULLETIN, vol. 27, no. 10, 31 October 2011 (2011-10-31), pages 1333 - 1337, ISSN: 1001-1978 * |
See also references of EP3210616A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019037067A1 (zh) * | 2017-08-25 | 2019-02-28 | 法玛科技顾问股份有限公司 | 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用以治疗及控管动脉粥状硬化的用途 |
Also Published As
Publication number | Publication date |
---|---|
EP3210616A1 (en) | 2017-08-30 |
JP2019196409A (ja) | 2019-11-14 |
EP3211004A4 (en) | 2018-05-30 |
EP3210616A4 (en) | 2018-06-13 |
JP2017537071A (ja) | 2017-12-14 |
TW201615215A (zh) | 2016-05-01 |
WO2016062280A1 (zh) | 2016-04-28 |
CN107206051A (zh) | 2017-09-26 |
TWI576112B (zh) | 2017-04-01 |
EP3211004A1 (en) | 2017-08-30 |
JP6860480B2 (ja) | 2021-04-14 |
TWI566780B (zh) | 2017-01-21 |
JP2018502055A (ja) | 2018-01-25 |
EP3211004C0 (en) | 2023-12-06 |
TW201615214A (zh) | 2016-05-01 |
CN107108719A (zh) | 2017-08-29 |
EP3211004B1 (en) | 2023-12-06 |
US20180044413A1 (en) | 2018-02-15 |
US20180134782A1 (en) | 2018-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109789196B (zh) | 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法 | |
Dellon et al. | Biologics in eosinophilic gastrointestinal diseases | |
WO2018102597A1 (en) | Methods of treating inflammatory conditions | |
US20210386855A1 (en) | Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist | |
TW202037604A (zh) | 治療掌蹠膿疱症之抗il-36r抗體 | |
WO2023001304A1 (zh) | 预防、缓解或治疗黏膜黏连的药物及其应用 | |
US20120308564A1 (en) | Treatment of a metabolic disorder | |
NL2024544B1 (en) | Compositions And Methods For Cancer Therapy | |
KR20230023663A (ko) | Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법 | |
WO2016062282A1 (zh) | 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用以保护胰脏及防止血糖升高的用途 | |
WO2012033518A1 (en) | Methods and compositions for treating metabolic disorders | |
TW202033558A (zh) | 化膿性汗腺炎治療中使用的抗cd40抗體 | |
Yuan et al. | Eptinezumab | |
JP7317377B2 (ja) | ストレス負荷が関与する疾患を予防及び/又は治療するための医薬 | |
AU2017367691B2 (en) | Methods of treating inflammatory conditions | |
EP3389704B1 (en) | Vaccination against diabetes, obesity and complications thereof | |
US20190218284A1 (en) | Methods of treating eosinophilic gastrointestinal diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15851823 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15521116 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2017522350 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015851823 Country of ref document: EP |